CliffBio
small molecule

KETOTIFEN FUMARATE

KETOTIFEN FUMARATE

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameKETOTIFEN FUMARATE
Active ingredientKETOTIFEN FUMARATE
StrengthEQ 0.025% BASE
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalMay 2006
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.